Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma

被引：12

作者：

Suga, Hiraku ^{[1
]}

Sugaya, Makoto ^{[1
]}

Miyagaki, Tomomitsu ^{[1
]}

Kawaguchi, Makiko ^{[1
]}

Morimura, Sohshi ^{[1
]}

Kai, Hiromichi ^{[1
]}

Kagami, Shinji ^{[1
]}

Ohmatsu, Hanako ^{[1
]}

Fujita, Hideki ^{[1
]}

Asano, Yoshihide ^{[1
]}

Tada, Yayoi ^{[1
]}

Kadono, Takafumi ^{[1
]}

Sato, Shinichi ^{[1
]}

机构：

[1] Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 1138655, Japan

来源：

EUROPEAN JOURNAL OF DERMATOLOGY | 2013年 / 23卷 / 05期

关键词：

visfatin; atopic dermatitis; cutaneous T-cell lymphoma; mycosis fungoides; adipose tissue; COLONY-ENHANCING FACTOR; MYCOSIS-FUNGOIDES; RHEUMATOID-ARTHRITIS; ADIPOSE-TISSUE; MESSENGER-RNA; EXPRESSION; PSORIASIS; DISEASE; IL-22; INFLAMMATION;

D O I：

10.1684/ejd.2013.2107

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Visfatin, a novel adipocytokine, is related with chronic inflammatory diseases, especially those characterized by T helper (Th)1-type immune responses. In this study, we examined serum visfatin levels in patients with atopic dermatitis (AD) or cutaneous T-cell lymphoma (CTCL), both of which are Th2-dominant diseases. Serum visfatin levels in patients with AD or advanced stage CTCL were significantly elevated compared to healthy controls. In CTCL patients, serum visfatin levels significantly decreased after treatment. Serum visfatin levels correlated with eosinophil counts in AD patients, whereas they correlated with the visual analogue scale itch scores and serum C-C motif ligand (CCL) 11 and CCL26 levels in CTCL patients. Visfatin expression by adipose tissue in lesional skin of AD and advanced stage CTCL was enhanced compared to that of healthy controls. These results suggest that visfatin may also be important in the development of Th2-dominant diseases as well as in Th1-type diseases.

引用

页码：629 / 635

页数：7

共 50 条

[21] BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma
Ohmatsu, H.
Sugaya, M.
Miyagaki, T.
Suga, H.
Fujita, H.
Asano, Y.
Tada, Y.
Kadono, T.
Sato, S.
BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (02) : 359 - 367
[22] Immunosequencing applications in cutaneous T-cell lymphoma
Mandel, Jenna
Gleason, Laura
Joffe, Daniel
Bhatti, Safiyyah
Nikbakht, Neda
FRONTIERS IN IMMUNOLOGY, 2023, 14
[23] Expression Profiles of Genes Encoding Cornified Envelope Proteins in Atopic Dermatitis and Cutaneous T-Cell Lymphomas
Trzeciak, Magdalena
Olszewska, Berenika
Sakowicz-Burkiewicz, Monika
Sokolowska-Wojdylo, Malgorzata
Jankau, Jerzy
Nowicki, Roman Janusz
Pawelczyk, Tadeusz
NUTRIENTS, 2020, 12 (03)
[24] Increased serum levels of interleukin 33 in patients with atopic dermatitis
Tamagawa-Mineoka, Risa
Okuzawa, Yasutaro
Masuda, Koji
Katoh, Norito
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : 882 - 888
[25] Phototherapy for Cutaneous T-Cell Lymphoma
Marka, Arthur
Carter, Joi B.
DERMATOLOGIC CLINICS, 2020, 38 (01) : 127 - +
[26] Management of cutaneous T-cell lymphoma
Duhovic, Chris
Child, Fiona
Wain, E. Mary
CLINICAL MEDICINE, 2012, 12 (02) : 160 - 164
[27] Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma
Geskin, Larisa J.
Akilov, Oleg E.
Lin, Yan
Lokshin, Anna E.
EXPERIMENTAL DERMATOLOGY, 2014, 23 (08) : 598 - 600
[28] Diagnosis and Management of Cutaneous Lymphomas Including Cutaneous T-cell Lymphoma
Zic, John A.
MEDICAL CLINICS OF NORTH AMERICA, 2021, 105 (04) : 737 - 755
[29] Emerging drugs for the treatment of cutaneous T-cell lymphoma
Cheng, Melissa
Zain, Jasmine
Rosen, Steven T.
Querfeld, Christiane
EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (01) : 45 - 54
[30] Canine cutaneous epitheliotropic T-cell lymphoma: a review
Fontaine, J.
Bovens, C.
Bettenay, S.
Mueller, R. S.
VETERINARY AND COMPARATIVE ONCOLOGY, 2009, 7 (01) : 1 - 14

← 1 2 3 4 5 →